Trelleborg Ab B Fria (PK) Stock Quote TBABF - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

32.25

Bid

34.88

Ask

39.84

Volume

0.00 Day's Range 0.00

25.50 52 Week Range 37.95

Market Cap

7.309B

Previous Close

32.25

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

125

Shares Outstanding

226,625,919

Dividend Yield

PE Ratio

0.73

Earnings Per Share (EPS)

44.46

Revenue

39.39B

Net Profit

10.08B

Sector

Molded, Extr Mech Rubber Gds

Industry

Plastics

Website

www.trelleborg.com

Headquarters

Trelleborg, Swe

Founded

1984

Trelleborg Ab B Fria (PK) is listed in the Molded, Extr Mech Rubber Gds sector of the OTCMarkets with ticker TBABF. The last closing price for Trelleborg Ab B Fria (PK) was $32.25. Over the last year, Trelleborg Ab B Fria (PK) shares have traded in a share price range of $ 25.50 to $ 37.95.

Trelleborg Ab B Fria (PK) currently has 226,625,919 shares outstanding. The market capitalization of Trelleborg Ab B Fria (PK) is $7.31 billion. Trelleborg Ab B Fria (PK) has a price to earnings ratio (PE ratio) of 0.73.

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune...

Amgen Completes Acquisition Of Otezla® (apremilast)

Amgen Completes Acquisition Of Otezla® (apremilast) Differentiated Therapy Strengthens Amgen's Long-Standing Expertise in Inflammation PR Newswire THOUSAND OAKS, Calif., Nov. 21, 2019 THOUSAND...

Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristo...

Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to...

CELGENE ERHÄLT DIE ZULASSUNGSEMPFEHLUNG DES CHMP FÜR LENALIDOMID (REVLIMID®) IN KOMBINATION MIT RITUXIMAB ZUR BEHANDLUNG V...

Die Kombination aus Lenalidomid (REVLIMID®) und Rituximab (R2) hat das Potenzial, eine chemotherapiefreie Behandlungsoption für rezidivierte oder refraktäre Patienten mit follikulärem Lymphom zu...

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500 PR Newswire NEW YORK, Nov. 19, 2019 NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc...

Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the...

Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult...

REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing PR Newswire WALTHAM...

FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...

REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients Approval of REBLOZYL marks the first FDA-approved treatment for...

Celgene to Present New & Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annua...

Nearly 70 abstracts, including more than 20 oral presentations highlight diverse portfolio of innovative treatment modalities, including potentially transformative cell therapies Celgene...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	-5.7	-15.0197628458	37.95	37.95	32.25	125	35.67	CS
12	-5.7	-15.0197628458	37.95	37.95	32.25	125	35.67	CS
26	-5.7	-15.0197628458	37.95	37.95	32.25	125	35.67	CS
52	6.75	26.4705882353	25.5	37.95	25.5	934	31.29458255	CS
156	9.5	41.7582417582	22.75	37.95	19.32	578	28.94069047	CS
260	19.25	148.076923077	13	37.95	13	503	25.41895854	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ELYSElys BMG Group Inc (CE)	$ 0.0021 (209,900.00%)	12.08k
WTERAlkaline Water Company Inc (CE)	$ 0.001 (99,900.00%)	44.78k
MOTNFPowertap Hydrogen Capital Corporation (CE)	$ 0.07 (69,900.00%)	6.75k
GDMIFGreen Mining Innovation Inc (PK)	$ 0.201 (28,614.29%)	100
TRLFFMaven Brands Inc (CE)	$ 0.013 (12,900.00%)	580
FTDLFirsTime Design Limited (CE)	$ 0.000001 (-99.89%)	1.58k
ASKEAlaska Pacific Energy Corporation (CE)	$ 0.000001 (-99.80%)	2.8M
SPRNSupernova Energy Inc (CE)	$ 0.000001 (-99.50%)	28.82k
NTRRNeutra Corporation (CE)	$ 0.000001 (-99.50%)	136
MJWLMajic Wheels Corp (CE)	$ 0.000001 (-99.50%)	25.2k
ABQQAB International Group Corporation (PK)	$ 0.0009 (12.50%)	174M
GSTCGlobestar Therapeutics Corporation (PK)	$ 0.0005 (-28.57%)	149.54M
AAPJAAP Inc (PK)	$ 0.0001 (0.00%)	140.19M
ASIIAccredited Solutions Inc (PK)	$ 0.00135 (-10.00%)	135.88M
ICBUIMD Companies Inc (PK)	$ 0.0018 (5.88%)	134.86M